Sunny Side Up: How Sun Pharma Yielded Blazing Returns of 18,800%

If you had invested ₹1 lakh in Sun Pharma way back in 1999, then you could have had ₹1.9 crores today! This multibagger gave massive returns of 18,800%. Let’s take a closer look at the company.

🧪 Stock: Sun Pharmaceutical Industries Ltd.

🧪 NSE: $SUNPHARMA

🌱 The Roots

1983: Sun Pharmaceutical Industries Ltd. was established. The business started off in Kolkata with just five psychiatric illness-treating goods. At Vapi, a small production facility for tablets and capsules was established. Sales were initially restricted to two East-Indian states.

1986: The business established an administrative office in Mumbai and they expanded client coverage to a few Indian cities in the West.

1987: They began expanding their marketing efforts across the country.

1988: The company introduced Monotrate and Angizem medicines.

1989: They introduced products used in gastroenterology.

🔎 Speciality

The company, which is ranked No. 1 in India and No. 8 in the US, is the fourth-largest speciality generic manufacturer in the world. It ranks as one of the top Indian pharmaceutical businesses in emerging markets and is the biggest in the US. The business produces and sells a wide range of pharmaceutical formulations for both acute and chronic treatments. It covers over-the-counter (OTC) medications, antiretrovirals (ARVs), branded generics, sophisticated or challenging-to-manufacture goods, active pharmaceutical ingredients (APIs) and intermediates.

More than 2000 high-quality compounds are included in the product portfolio, which also includes tablets, capsules, injectables, inhalers, ointments, lotions and liquids among other dosage forms. It launched its IPO in 1994 and has been giving its investors massive returns.

💸 Stock Prices

During the pandemic, the company saw its profit margins beat estimates by a wide margin and the stock prices soared. On August 6, 1999, the share prices were ₹4.85 a piece, while they are currently trading at ₹916.50 as of August 5, 2022.